The Latest Breaking News on Pharma

J&J's patent on bedaquiline expired, allowing generic manufacturers to supply the drug. J&J has filed secondary patents. Prices are expected to reduce 3-6x, but some countries are excluded from the deal, raising concerns.

A tornado that tore through eastern North Carolina and struck a large Pfizer pharmaceutical plant has damaged its drug storage facility but not its medicine production areas

Concerns of weight loss and Type 1 diabetes are fueling the rise of our choice for this week's option position in shares of Novo Nordisk.

Abbott Laboratories’ sales of COVID-19 tests fell by a whopping 89% during the second quarter of this year compared with the same time last year — a drop that comes as the world attempts to move on from the pandemic.

Here's what may happen to J&J's shares next.

The future of the medical devices and equipment industry looks buoyant, given rising chronic conditions and the adoption of advanced technology. Given this backdrop, would it be prudent for investors to buy medical stocks, Terumo Corporation (TRUMY), Haemonetics Corp. (HAE), and MiMedx Group (MDXG)? Read more to find out….

Novo Nordisk stock is Thursday's IBD Stock Of The Day. Shares bounded above their 50-day line, giving investors a new entry.

U.S. hospital drug supplies may be strained further after a tornado ripped open the roof of a Pfizer factory this week

“We are entering the back half of the year from a position of strength with numerous catalysts, including becoming a two-sector company focused on Pharmaceutical and MedTech innovation," said CEO Joaquin Duato.

The U.S. Drug Enforcement Administration’s second-in-command has quietly stepped down amid reporting by The Associated Press that he previously consulted for a pharmaceutical distributor sanctioned for a deluge of suspicious painkiller shipments and did similar work for the drugmaker that became the face of the opioid epidemic: Purdue Pharma

The new Bill, to regulate drugs and medical devices, was formulated without input from major stakeholders, device manufacturers claim. They also want a separate law for regulation of their industry.